Diagnosis of liver pathology through assessment of protein glycosylation

Patent metadata

Field	Value
Publication number	US-10082512-B2
Application number	US-91334806-A
Country	US
Kind code	B2
Filing date	May 5, 2006
Priority date	May 5, 2005
Publication date	Sep 25, 2018
Grant date	Sep 25, 2018

Abstract

Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.

First claim

What is claimed:

1. A kit for assessing the pathological status of a liver in a subject suspected of having a liver pathology comprising:
a deglycosylated capture reagent for isolating from a biological fluid a protein selected from GP73, HBsAg, hepatitis B viral particle, alpha-1-antichymotrypsin, alpha-1-antichymotrypsin His-Pro-less, Ceruloplasmin, alpha-2-macroglobulin, Haptoglobin, Fibrinogen gamma chain precursor, APO-D, Kininogen, Histidine rich glycoprotein, Complement factor 1 precursor, complement factor I heavy chain, complement factor I light chain, Complement C1s, Complement factor B precursor, complement factor B Ba fragment, Complement factor B Bb fragment, Complement C3 precursor, Complement C3 beta chain, Complement C3 alpha chain, C3a anaphylatoxin, Complement, C3b alpha′ chain, Complement C3c fragment, Complement C3dg fragment, Complement C3g fragment, Complement C3d fragment, Complement C3f fragment, Complement C5, Complement C5 beta chain, Complement C5 alpha chain, C5a anaphylatoxin, Complement C5 alpha′ chain, Complement C7, alpha-1 B glycoprotein, Vitamin D-binding protein, Inter-alpha-trypsin inhibitor heavy chain H2, Alpha-1B-glycoprotein, Angiotensinogen precursor, Angiotensin-1, Angiotensin-2, Angiotensin-3, GARP protein, beta-2-glycoprotein, Clusterin (Apo J), Integrin alpha-8 precursor glycoprotein, Integrin alpha-8 heavy chain, Integrin alpha-8 light chain, hepatitis C viral particle, elf-5, HSP33-homolog, lysyl endopeptidase or Leucine-rich repeat-containing protein 32 precursor, wherein said capture reagent for isolating said protein is specific to said protein;
a reagent that binds to core fucosyl moieties on said isolated protein, wherein the binding of said reagent is determinative as to the presence of a core fucosyl moiety on said protein;
a detection reagent for detecting the reagent bound to the fucosyl moieties to provide a detected core fucosylation value, and instructions for using the kit in a method for assessing the pathological status of the liver by comparing the detected core fucosylation value with a reference value for core fucosylation on said protein in a comparable biological fluid of subjects without said liver pathology, said detected core fucosylation value relative to the reference value being indicative of the presence or absence of said liver pathology, wherein a detected core fucosylation value that deviates from said reference value to a statistically significant degree is indicative of the presence of said liver pathology,
or
comparing the detected core fucosylation value with a reference value for core fucosylation on said protein in a comparable biological fluid of subjects in which said liver pathology is known to be present, said detected core fucosylation value relative to the reference value being indicative of the presence or absence of said liver pathology, wherein a detected core fucosylation value that deviates from said reference value to a statistically significant degree is indicative of the absence of said liver pathology.

2. The kit of claim 1 , wherein said reagent that binds to fucosyl moieties comprises a molecule that directly labels an oligosaccharide.

3. The kit of claim 1 , wherein said reagent that binds to fucosyl moieties comprises a molecule that is coupled to a detectable moiety.

4. The kit of claim 1 further comprising a secondary reagent that specifically recognizes said reagent that binds to fucosyl moieties, wherein said secondary reagent is coupled to a detectable moiety.

5. The kit of claim 1 wherein said reagent that binds to fucosyl moieties comprises a lectin.

6. The kit of claim 1 further comprising a solid support to which said capture reagent for isolating said protein is coupled.

7. The kit of claim 1 further comprising a positive control, a negative control, or both.

8. The kit of claim 1 wherein said reagents and said instructions are configured to permit multiple assessments using said kit.

9. The kit of claim 1 wherein said capture reagent for isolating said protein is an antibody.

10. The kit of claim 1 , wherein the capture reagent for isolating said protein is specific to kininogen.

Assignees

• Block Timothy M
• Mehta Anand
• Comunale Mary Ann
• Univ Drexel

Inventors

• Block Timothy M
• Mehta Anand
• Comunale Mary Ann

Classifications

• G01N2800/085

  Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin · CPC title

• G01N2800/08

  Hepato-biliairy disorders other than hepatitis · CPC title

• G01N2333/4728

  alpha-Glycoproteins · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title

• G01N2800/7028

  Cancer · CPC title